SNDX-4321 — IND submission
Late 2026
The Company expects to submit an investigational new drug (IND) application for SNDX-4321 by the end of 2026 and to initiate a Phase 1 trial in EGFRm NSCLC in 2027.Source filing
SNDX biotech catalysts & pipeline
SYNDAX PHARMACEUTICALS INC · Data as of 2026-09-08
Upcoming catalysts
axatilimab — Topline data
Q4 2026
The Company anticipates topline data from MAXPIRe, a Phase 2, 26-week randomized, double-blinded, placebo-controlled trial of axatilimab on top of standard of care in patients with idiopathic pulmonary fibrosis in the fourth quarter of 2026.Source filing
Revuforj (revumenib) — Full data
Q4 2026
The Company expects to publish safety and efficacy data from R/R NUP98r acute leukemia patients treated with revumenib in the fourth quarter of 2026.Source filing
SNDX-62122 — IND submission
2027
The Company expects to submit an IND and initiate a Phase 1 trial of SNDX-62122 in MF in 2027.Source filing
Revuforj (revumenib) — Initial data
H2 2027
The development of SNDX-62122 will be informed by a Phase 1/2 proof-of-principle trial of revumenib in MF that is expected to initiate in the fourth quarter of 2026 with initial clinical data expected in the second half of 2027.Source filing
axatilimab — Topline data
early 2028
Topline data are anticipated in early 2028.Source filing
Niktimvo (axatilimab-csfr) — Topline data
early 2028
Topline data is anticipated in early 2028.Source filing
Revuforj (revumenib) — Conference presentation
H2 2026
The Company expects to have a major presence at upcoming medical meetings in the second half of 2026 with the presentation of new/updated revumenib data including:Source filing